^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NRAS wild-type

    i
    Other names: NRAS1, N-Ras Protein Part 4, Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, NRAS, Neuroblastoma RAS Viral Oncogene Homolog, NRAS Proto-Oncogene, GTPase
    Entrez ID:
    4893
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    19h
    FALCO: Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases (clinicaltrials.gov)
    P2, N=40, Recruiting, Zhejiang University
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • KRAS G12C • BRAF mutation • NRAS mutation • BRAF wild-type • KRAS G12 • NRAS wild-type • NRAS G12
    |
    Erbitux (cetuximab) • Dupert (fulzerasib) • Datalai (cetuximab biosimilar)
    1d
    Case Report: Cerebral metastasis following standard therapy in BRAF/KRAS wild-type colorectal cancer: an unusual presentation of disease progression. (PubMed, Front Oncol)
    Overall, she had an unusual pattern of disease progression in molecularly low-risk CRC, indicating that delayed CNS metastasis can occur despite apparent systemic remission. These findings challenge current assumptions regarding CNS risk stratification in CRC and raise important questions about the need for individualized neurological surveillance strategies in selected patient subgroups.
    Journal • Tumor mutational burden
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    TP53 mutation • KRAS mutation • BRAF mutation • NRAS mutation • KRAS wild-type • BRAF wild-type • TMB-L • RAS wild-type • NRAS wild-type
    6d
    Dual inhibition of GTP-bound (ON) and GDP-bound (OFF) KRAS G12C suppresses PI3Kα and leads to potent tumor inhibition. (PubMed, bioRxiv)
    BBO-8520 exerted more potent and sustained inhibition of KRAS G12C and anti-tumor activity in vitro and in vivo compared with sotorasib, a KRAS G12C (OFF)-only inhibitor...Moreover, in some contexts, disruption of RAS-PI3Kα further increased the anti-tumor activity of BBO-8520 monotherapy. These results reveal mechanistic differences between KRAS (ON) and (OFF) inhibitors, highlight the importance of PI3Kα-AKT signaling in driving resistance to KRAS inhibition in lung cancer, and suggest combination strategies that suppress PI3Kα-AKT to improve the response to KRAS inhibitors.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • KRAS G12C • RAS wild-type • NRAS wild-type • NRAS G12
    |
    Lumakras (sotorasib)
    22d
    PK equivalence: A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs. ERBITUX® in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=387, Not yet recruiting, Shanghai Henlius Biotech
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium
    29d
    Hyperprogression after Anti-Programmed Death-1 Therapy in a Case of Sigmoid Colon Cancer with Lynch Syndrome. (PubMed, Surg Case Rep)
    This case underscores the importance of early response evaluation in ICI-treated MSI-H tumors. Rapid disease progression requires prompt differentiation between HPD and pseudoprogression, emphasizing the necessity of timely therapeutic modification.
    Journal • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog) • MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2)
    |
    KRAS mutation • MSI-H/dMMR • BRAF mutation • RAS wild-type • NRAS wild-type • KRAS G13 • NRAS G13
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium
    2ms
    aCCeleR8-001: S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1/2, N=282, Recruiting, Shionogi | Trial completion date: Apr 2027 --> May 2028 | Trial primary completion date: Apr 2027 --> May 2028
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    BRAF V600E • BRAF V600 • KRAS wild-type • RAS wild-type • NRAS wild-type
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • S-531011
    2ms
    GFH009X2101: Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Sellas Life Sciences Group | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • FLT3 (Fms-related tyrosine kinase 3) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • NPM1 (Nucleophosmin 1) • SF3B1 (Splicing Factor 3b Subunit 1) • ASXL1 (ASXL Transcriptional Regulator 1) • SRSF2 (Serine and arginine rich splicing factor 2) • BCOR (BCL6 Corepressor) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1) • STAG2 (Stromal Antigen 2) • DDX41 (DEAD-Box Helicase 41) • ZRSR2 (Zinc Finger CCCH-Type, RNA Binding Motif And Serine/Arginine Rich 2)
    |
    TP53 mutation • KRAS mutation • FLT3-ITD mutation • Chr del(17p) • IDH1 mutation • IDH2 mutation • FLT3 mutation • TP53 wild-type • NPM1 mutation • KRAS wild-type • Chr del(11q) • ASXL1 mutation • SF3B1 mutation • EZH2 mutation • NRAS wild-type • SRSF2 mutation • IDH wild-type
    |
    Venclexta (venetoclax) • azacitidine • tambiciclib (SLS009)
    2ms
    Molecular Profiling and Matched Targeted Therapy for Patients With Advanced Melanoma: Results From Part 1 of the MatchMEL Study. (PubMed, JCO Precis Oncol)
    Our findings suggest significant clinical, pathologic, and molecular correlations in an Australian cohort of advanced melanoma treated with ICIs. Patients with NF1 mutation exhibited higher TMB, which was associated with improved response to ICIs.
    Journal • Tumor mutational burden • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NF1 (Neurofibromin 1)
    |
    TMB-H • BRAF mutation • NRAS mutation • BRAF V600 • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    FoundationOne® CDx
    2ms
    EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=2, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Jul 2025 --> Feb 2026
    Trial primary completion date
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene)
    |
    KRAS wild-type • BRAF wild-type • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • CimaVax EGF (EGF-PTI)
    2ms
    LCCC1717: Palbociclib and Cetuximab in Metastatic Colorectal Cancer (clinicaltrials.gov)
    P2, N=24, Completed, UNC Lineberger Comprehensive Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS wild-type • NRAS wild-type
    |
    Erbitux (cetuximab) • Ibrance (palbociclib)
    2ms
    E7386-J081-102: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (clinicaltrials.gov)
    P1/2, N=301, Active, not recruiting, Eisai Inc. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2027 --> Mar 2027 | Trial primary completion date: Aug 2027 --> Mar 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600 • KRAS wild-type • NRAS wild-type
    |
    paclitaxel • Lenvima (lenvatinib) • doxorubicin hydrochloride • E7386
    3ms
    Combating colorectal lung metastases via systemic therapy and thermal ablation: RAS mutation impact. (PubMed, Int J Surg)
    RAS mutations are independent predictors of poor local control and survival after IGTA in CRLM. Evaluate interactions between RAS genotype and commonly used targeted agents in the peri-ablative setting. These integrated, real-world insights support the development of genotype-guided ablation planning and peri-ablative systemic therapy strategies.
    Retrospective data • Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    KRAS mutation • NRAS mutation • KRAS wild-type • RAS mutation • RAS wild-type • NRAS wild-type
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • leucovorin calcium